Catcher Technology (2474) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
31 Mar, 2026Executive summary
Q3 2024 revenue rose 18.1% year-over-year to NT$5,117bn, driven by improved shipments and a low base effect.
Gross margin improved to 34.5%, up 10.7pp year-over-year, reflecting scale and product mix optimization.
Net profit after tax dropped 68.1% year-over-year due to significant FX losses, with Q3 2024 net profit at NT$1,430.1 million.
EBITDA increased to NT$1.624bn, up 75.9% year-over-year.
The company completed the delisting of its Global Depositary Receipts from the Luxembourg Stock Exchange in June 2024.
Financial highlights
Q3 2024 revenue: NT$5.117bn; gross profit: NT$1.767bn; operating profit: NT$1.198bn.
Q3 2024 basic EPS: NT$2.10 vs. NT$6.59 in Q3 2023; nine-month net profit: NT$9.441bn, down 4.2% year-over-year.
9M 2024 revenue: NT$13.448bn, down 8.9% year-over-year; gross margin: 32.5%, up 4.6pp.
Cash and cash equivalents at September 30, 2024 were NT$36.8bn, down from NT$69.7bn a year earlier.
Significant FX losses of NT$1.763bn in Q3 2024; FX gains of NT$2.122bn in 9M 2024.
Outlook and guidance
Narrowing year-over-year revenue decline in 9M 2024 suggests recovering demand.
The company remains focused on sustainable operations and long-term development, with a dividend policy emphasizing stability and growth.
Latest events from Catcher Technology
- H1 2024 net profit rose 49% despite a 20% revenue drop, supported by FX gains and strong liquidity.2474
Q2 202431 Mar 2026 - Net profit jumped 44% to NT$13.20bn on stable revenue, margin gains, and high dividends.2474
Q4 202431 Mar 2026 - Gross margin reached 35% as revenue grew 18.9% year-over-year, but net profit fell sharply.2474
Q1 202531 Mar 2026 - 2Q25 revenue increased, but FX losses and margin pressure led to a net loss; diversification continues.2474
Q2 202531 Mar 2026 - 3Q25 net profit more than doubled year-over-year despite a 5% revenue decline.2474
Q3 202531 Mar 2026 - 4Q25 revenue fell, but gross margin rose; 2025 profit and EPS dropped despite medtech growth.2474
Q4 202531 Mar 2026